A5101440707- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- HIV, Drug Use, Sexual Risk
- Vaccine Coverage and Hesitancy
- HIV/AIDS Research and Interventions
- Adolescent Sexual and Reproductive Health
- COVID-19 epidemiological studies
- Sex work and related issues
- HIV Research and Treatment
- Influenza Virus Research Studies
- HIV, TB, and STIs Epidemiology
- Long-Term Effects of COVID-19
- Infection Control and Ventilation
- Intramuscular injections and effects
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- Heparin-Induced Thrombocytopenia and Thrombosis
- Census and Population Estimation
- Vitamin C and Antioxidants Research
- Syphilis Diagnosis and Treatment
- SARS-CoV-2 detection and testing
- HIV/AIDS Impact and Responses
- HIV/AIDS drug development and treatment
- Infectious Encephalopathies and Encephalitis
- Cervical Cancer and HPV Research
Sinovac Biotech
2020-2023
Suzhou Municipal Hospital
2020
Nanjing Medical University
2020
Sichuan Center for Disease Control and Prevention
2019
Center for Disease Control
2015
Chinese Center For Disease Control and Prevention
2009-2014
Centers for Disease Control and Prevention
2014
National Center for AIDS/STD Control and Prevention,China CDC
2008-2010
Sichuan University
2005
With the unprecedented morbidity and mortality associated with COVID-19 pandemic, a vaccine against is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated candidate COVID-19, containing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for its safety, tolerability immunogenicity.In this randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, healthy adults aged 18-59 years were recruited from community in Suining...
The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports results obtained for healthy Chilean adults aged ≥18 years in phase 3 clinical trial.Volunteers randomly received doses or placebo, separated by weeks. A total 434 volunteers were enrolled, 397 18-59 37 ≥60 years. Solicited unsolicited adverse...
ABSTRACT BACKGROUND The top priority for the control of COVID-19 pandemic currently is development a vaccine. A phase 2 trial conducted to further evaluate immunogenicity and safety SARS-CoV-2 inactivated vaccine (CoronaVac). METHODS We randomized, double-blind, placebo-controlled optimal dose, CoronaVac. total 600 healthy adults aged 18-59 years were randomly assigned receive injections at dose 3 μg/0.5 mL or 6 μg /0.5mL, placebo on Day 0,14 schedule 0,28 schedule. For evaluation, solicited...
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible of current pandemic ongoing all around world. Since its discovery in 2019, several circulating variants have emerged and some them are associated with increased infections death rate. Despite genetic differences among these variants, vaccines approved for human use shown a good immunogenic protective response against them. In Chile, over 70% vaccinated population immunized CoronaVac, an...
Abstract Background Large-scale vaccination is being implemented globally with CoronaVac, an inactivated vaccine against coronavirus disease 2019 (COVID-19). Immunogenicity and safety profiles of homologous two-dose schedules have been published. We report interim results immune persistence, the immunogenicity a third dose CoronaVac. Methods In this ongoing, placebo-controlled, double-blind phase 2 trial in 18-to-59-year-olds, we randomly assigned subjects, 1:1:1:1, to one four receive dose,...
Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are actively carried out around the world. Several vaccines currently approved for emergency use in population, while ongoing studies continue provide information on their safety and effectiveness. CoronaVac is an inactivated SARS-CoV-2 vaccine with a good immunogenicity profile as seen phase 1, 2, 3 clinical trials world, effectiveness of 65.9% symptomatic cases. Although vaccination...
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. rapid development of safe protective vaccines against this disease is global priority. CoronaVac vaccine prototype based on inactivated SARS-CoV-2, which shown promising safety immunogenicity profiles in pre-clinical studies phase 1/2 trials China. To day, four 3 clinical are Brazil, Indonesia, Turkey, Chile. This article reports the results obtained subgroup participants...
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 4 weeks after two doses CoronaVac; these were significantly reduced at 6 to 8 months doses. Here, we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOCs), Delta Omicron, in adults participating phase III clinical trial Chile. Volunteers immunized with...
Monoclonal antibodies (mAbs) and the post-exposure prophylaxis (PEP) with mAbs represent a very important public health strategy against coronavirus disease 2019 (COVID-19). This study has assessed new Anti-SARS-COV-2 mAb (SA58) Nasal Spray for PEP COVID-19 in healthy adults aged 18 years older within three days of exposure to SARS-CoV-2 infected individual. Recruited participants were randomized ratio 3:1 receive SA58 or placebo. Primary endpoints laboratory-confirmed symptomatic period. A...
BackgroundThe Omicron variant has challenged the control of COVID-19 pandemic due to its immuno-evasive properties. The administration a booster dose SARS-CoV-2 vaccine showed positive effects in immunogenicity against SARS-CoV-2, effect that is even enhanced after second booster.MethodsDuring phase-3 clinical trial, we evaluated CoronaVac®, an inactivated administered 6 months first booster, neutralization (n = 87). In parallel, cellular immunity 45) was analyzed stimulated peripheral...
To assess the predictors and prevalence of HIV infection among injection drug users in highly endemic regions along major trafficking routes three Chinese provinces. We enrolled participants using community outreach peer referrals. uestionnaire-based interviews provided demographic, use, sexual behavior information. was tested via ELISA syphilis by RPR. Of 689 participants, 51.8% were HIV-infected, with persons living Guangxi having significantly lower (16.4%) than those from Xinjiang Yunnan...
Objective . This study was to characterize the continuously changing trends of HIV prevalence, risks, sexual behaviors, and testing behaviors among men who have sex with (MSM) in Chongqing, China. Methods Five consecutive cross-sectional surveys were conducted MSM 2006, 2008, 2010, 2012, 2013. Testing for syphilis performed, behavior, prevention, behavior collected using same questionnaire. Results prevalence increased from 13.0% 19.7% 2006 2013 (<mml:math...
People living with chronic disease, particularly seniors (≥60 years old), made up of most severe symptom and death cases among SARS-CoV-2 infected patients. However, they are lagging behind in the national COVID-19 vaccination campaign China due to uncertainty vaccine safety effectiveness. Safety immunogenicity data vaccines people underlying medical conditions needed address hesitation this population.We included participants (≥40 old) who received two doses CoronaVac inactivated (at a 3-5...
Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials China, Brazil, Indonesia, Turkey, Chile. Methods: This study randomized, multicenter, controlled phase 3 trial healthy Chilean adults aged ≥18 years. Volunteers received two doses...
The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with high capacity against different Omicron sub-variants in vitro studies.This study demonstrated safety and effectiveness coronavirus disease 2019 (COVID-19) infection medical personnel for first time.This provides an effective approach public to reduce their risk COVID-19 infection. findings this research have potential significantly limit human-to-human transmission event outbreak.
Abstract Background Today’s rapid growth of migrant populations has been a major contributor to the human immunodeficiency virus (HIV) epidemic. However, relatively few studies have focused on HIV/acquired syndrome (AIDS)-related knowledge, attitudes, and practice among rural-to-urban migrants in China. This cross-sectional study was assess HIV/AIDS-related knowledge perceptions, including about reducing high-risk sex. Methods Two-phase stratified cluster sampling applied 2,753 rural...